Bellerophon Therapeutics (NASDAQ:BLPH) Now Covered by Analysts at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Get Free Report) in a research report issued on Sunday. The firm set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

Shares of Bellerophon Therapeutics stock opened at $0.04 on Friday. Bellerophon Therapeutics has a 1 year low of $0.03 and a 1 year high of $0.42. The firm’s 50-day simple moving average is $0.04 and its 200-day simple moving average is $0.05. The firm has a market cap of $440,388.00, a PE ratio of -0.04 and a beta of 0.70.

Bellerophon Therapeutics Company Profile

(Get Free Report)

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.

Further Reading

• Five stocks we like better than Bellerophon Therapeutics
• Stock Sentiment Analysis: How it Works
• TJX Stock: A Buying Opportunity Before the Holiday Rush
• How is Compound Interest Calculated?
• Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
• Election Stocks: How Elections Affect the Stock Market
• Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth